Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 2/20 | 0.52 |
| ▸ | NPY4R | P50391 | 7/20 | 0.50 |
| ▸ | NPY1R | P25929 | 5/20 | 0.50 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.50 |
| ▸ | NPY2R | P49146 | 4/20 | 0.50 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.50 |
| ▸ | TFPI | P10646 | 1/20 | 0.49 |
| ▸ | NTSR2 | O95665 | 1/20 | 0.48 |
| ▸ | NTSR1 | P30989 | 1/20 | 0.48 |
| ▸ | KISS1R | Q969F8 | 2/20 | 0.48 |
| ▸ | OXTR | P30559 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13633986 | 0.89 | NPY4R (0.58) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13634057 | 0.88 | F2 (0.55) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13634094 | 0.86 | BACE1 (0.55) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30445824 | 0.82 | NTSR2 (0.56) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL13638754 | 0.82 | F2 (0.54) | F2OPRD1TFPINTSR2NTSR1 | |
| SCHEMBL31114990 | 0.82 | NPY4R (0.55) | NPY4RNPY1RNPY5RNPY2ROPRD1 | |
| SCHEMBL29611881 | 0.82 | F2 (0.59) | F2OPRD1TFPINTSR2NTSR1 | |
| SCHEMBL18234195 | 0.82 | KISS1R (0.49) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL30445421 | 0.81 | NTSR2 (0.55) | F2NPY4RNPY1RNPY5RNPY2R | |
| SCHEMBL31182852 | 0.81 | TFPI (0.59) | TFPI |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-8304388-B2 | Imaging agents | GE HEALTHCARE LIMITED (GB) | 2012-11-06 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
| US-20090191123-A1 | NOVEL IMAGING AGENTS | GE HEALTHCARE LIMITED (GB) | 2009-07-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090191123-A1 | NOVEL IMAGING AGENTS | MMP1, CD68, KIT | F2 1249/4885NPY4R 3630/4885NPY1R 3482/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.